News & Updates

First HIV cure trial affirms tolerability of investigational combo in women with HIV

21 Mar 2025 by

A phase IIa study affirms the tolerable safety of a combination regimen comprising three investigational compounds – two broadly neutralizing antibodies (bNAbs), VRC07-523LS and CAP256V2LS, and the TLR7 agonist vesatolimod – in women with HIV-1.

First HIV cure trial affirms tolerability of investigational combo in women with HIV

21 Mar 2025

COVID-19 outcomes more severe than those of flu, RSV

21 Mar 2025

COVID-19 led to more severe disease outcomes than influenza or respiratory syncytial virus (RSV) during the 2022–2023 season, whereas the differences were attenuated in the subsequent season, as shown in a retrospective study.

COVID-19 outcomes more severe than those of flu, RSV

21 Mar 2025

Early sotrovimab use cuts risk of severe outcomes in high-risk COVID-19 patients

20 Mar 2025 by

Use of the monoclonal antibody sotrovimab within 10 days of COVID-19 diagnosis appears to reduce the risk of hospitalization, mortality, and need for respiratory support in patients at high risk of progression to severe illness, according to large real-world data.

Early sotrovimab use cuts risk of severe outcomes in high-risk COVID-19 patients

20 Mar 2025

Switch to B/F/TAF maintains viral suppression in people with HIV-1, HBV

20 Mar 2025 by

Following the switch from dolutegravir plus emtricitabine/tenofovir disoproxil fumarate (DTG+F/TDF), treatment with bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) has shown efficacy in keeping HIV-1 and hepatitis B virus (HBV) at low levels in the blood through 48 weeks of the open-label extension (OLE) phase of the ALLIANCE study.

Switch to B/F/TAF maintains viral suppression in people with HIV-1, HBV

20 Mar 2025

D-dimer predicts clinical outcomes in N. meningitidis infections

19 Mar 2025 by

Increasing D-dimer is a useful predictor of negative clinical outcomes among individuals with invasive infections driven by Neisseria Meningitidis, suggests a study.

D-dimer predicts clinical outcomes in N. meningitidis infections

19 Mar 2025

H56:IC31 vaccine of no help against TB recurrence

14 Mar 2025

For individuals who completed treatment for pulmonary tuberculosis (TB), vaccination with H56:IC31 does not appear to reduce the risk of disease recurrence, according to a phase 2b trial.

H56:IC31 vaccine of no help against TB recurrence

14 Mar 2025

Original New Drug Application Approvals by US FDA (16-28 February 2025)

14 Mar 2025

New drug applications approved by US FDA as of 16-28 February 2025 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (16-28 February 2025)

14 Mar 2025

SG sees drop in paediatric pneumococcal disease burden

13 Mar 2025 by

The introduction of pneumococcal conjugate vaccines (PCV) into Singapore's National Childhood Immunisation Schedule (NCIS) has reduced the incidence of invasive pneumococcal disease (IPD) in children by nearly a third, as reported in a study.

SG sees drop in paediatric pneumococcal disease burden

13 Mar 2025

Young adults unaware of male HPV infection, vaccine benefits

13 Mar 2025 by

Awareness about human papillomavirus (HPV) infection in males and the benefits of vaccination on both genders is low among young adults, reveals a Singapore study.

Young adults unaware of male HPV infection, vaccine benefits

13 Mar 2025

COVID-19 may leave lingering GI issues in children

10 Mar 2025 by

In children and adolescents who have contracted COVID-19, gastrointestinal (GI) tract symptoms may remain for up to 2 years, as reported in a large retrospective study.

COVID-19 may leave lingering GI issues in children

10 Mar 2025

News & Updates

Filter by Specialty:

Specialty:

First HIV cure trial affirms tolerability of investigational combo in women with HIV

First HIV cure trial affirms tolerability of investigational combo in women with HIV

COVID-19 outcomes more severe than those of flu, RSV

COVID-19 outcomes more severe than those of flu, RSV

Early sotrovimab use cuts risk of severe outcomes in high-risk COVID-19 patients

Early sotrovimab use cuts risk of severe outcomes in high-risk COVID-19 patients

Switch to B/F/TAF maintains viral suppression in people with HIV-1, HBV

Switch to B/F/TAF maintains viral suppression in people with HIV-1, HBV

D-dimer predicts clinical outcomes in N. meningitidis infections

D-dimer predicts clinical outcomes in N. meningitidis infections

H56:IC31 vaccine of no help against TB recurrence

H56:IC31 vaccine of no help against TB recurrence

Original New Drug Application Approvals by US FDA (16-28 February 2025)

Original New Drug Application Approvals by US FDA (16-28 February 2025)

SG sees drop in paediatric pneumococcal disease burden

SG sees drop in paediatric pneumococcal disease burden

Young adults unaware of male HPV infection, vaccine benefits

Young adults unaware of male HPV infection, vaccine benefits

COVID-19 may leave lingering GI issues in children

COVID-19 may leave lingering GI issues in children